Joint projects

Projects granted by the Ministry of Economy and Competitiveness of the Government of Spain, in which Reig Jofre participates:

  • Project PredictGYN

    Project title: DEVELOPMENT OF NEW APPROACHES IN THE INDIVIDUALIZED MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS (PredictGYN)
    Reference number: RTC-2015-3821-1
    Partners: Ability Pharmaceuticals SL
    Althia Health SL
    Fundacio Hospital Universitari Vall d'Hebron - Institut de Recerca
    Institut de Recerca Biomedica de Lleida
    Fundacio Privada Dr. Pifarre
    Laboratorio Reig Jofre SA
    Oryzon Genomics Diagnostico SL
    Funding Agency: Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016.
    Objective: Identification of molecular markers to develop a prognostic test for patients with endometrial and ovarian cancer. Development of new personalized therapy strategies in endometrial cancer.
    Duration: 2015-2018

  • Project NANOMUC

    Project title: DEVELOPMENT OF INNOVATIVE FORMULATIONS OF MUCOADHESIVE NANOPARTICLES FOR THE TREATMENT OF MUCOSAL ULCERS (NANOMUC)
    Reference number: RTC-2015-4437-1
    Partners: Bionanoplus SL
    Laboratorio Reig Jofre SA
    Universidad de Navarra
    Universidad de Sevilla
    Funding Agency: Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016.
    Objective: Development of controlled drug release treatments using innovative formulations of mucoadhesive polymeric nanoparticles. This will allow a longer residence of active principles in the mucous, combining local and systemic action, and resulting in a more effective treatment.
    Duration: 2015-2017

  • Project CURE4B

    Project title: CURE4B
    Reference number: RTC-2015-4319-1
    Partners: Fundacio per a la recerca i la docencia Sant Joan de Deu (FSJD)
    Institut Catala d’Oncologia
    Laboratorio Reig Jofre SA
    Vcn Biosciences SL
    Funding Agency: Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016.
    Objective: Development and validation of oncolytic virus VCN-01 as a clinical candidate for retinoblastoma treatment, the most common type of eye cancer in children.
    Duration:: 2015-2018

  • Project SIMBIO

    Project title: DEVELOPMENT OF HIGH EFFICIENCY SYSTEMS FOR THE PRODUCTION OF BIOSIMILAR ANTIBODIES, ANTI-VEGF (SIMBIO)
    Reference number: Expediente: IPT-2012-0663-090000
    Partners: Laboratorio Reig Jofre SA
    Bioingenium
    Centro Tecnologico Leitat
    Funding Agency: Ministry of Economy and Competitiveness, National Program of Public-Private Cooperation - INNPACTO subprogram, within the instrumental line of Articulation and Internationalization of the System, under the National Plan for Scientific Research, Development, and Technological Innovation 2008-2011.
    Objective: Optimize the production of anti-VEGF biosimilars. Production of the biosimilar of the active principle Ranibizumab, using E coli, and optimization of a eukaryotic cells platform for therapeutic proteins expression.
    Duration: 2012-2015

  • Project ADELVAC

    Project title: ADENOVIRUS WITHOUT ISOTOPES FOR VACCINATION (ADELVAC)
    Reference number: IPT-2012-0551-010000
    Partners: VCN Biosciences SL
    Laboratorio Reig Jofre SA
    ICO
    ISC III
    Funding Agency: Ministry of Economy and Competitiveness, National Program of Public-Private Cooperation - INNPACTO subprogram, within the instrumental line of Articulation and Internationalization of the System, under the National Plan for Scientific Research, Development, and Technological Innovation 2008-2011.
    Objective: Developing a new generation of vaccines based on adenovirus devoid of intrinsic immunogenicity, due to the withdraw of immunodominant epitopes, thus preventing activation of the immune system. New vectors carrying the appropriate antigens may be used for both therapeutic approach of chemoresistant tumors and treatment of infectious diseases.
    Duration: 2012-2014

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

DMC Firewall is developed by Dean Marshall Consultancy Ltd